Ozempic vs Mounjaro 2026: Which GLP-1 Is Better for Weight Loss?
Semaglutide and tirzepatide are the two dominant GLP-1 medications in 2026. We compare clinical trial results, mechanisms, side effects, dosing, and cost — including affordable compounded options starting at $99/month.
Quick Answer
Mounjaro (tirzepatide) produces greater average weight loss — up to 22.5% of body weight in clinical trials vs. about 15% for Ozempic (semaglutide). However, brand-name versions of both cost $1,000–$1,500/month. Compounded alternatives through providers like Trimi deliver the same active molecules starting at $99/month for semaglutide and $125/month for tirzepatide — 85–90% less expensive.
What Are Ozempic and Mounjaro? Brand Names Explained
Ozempic is the brand name for semaglutide, manufactured by Novo Nordisk. It was originally approved by the FDA for type 2 diabetes management in 2017. Ozempic and Wegovy contain the same active molecule — semaglutide — at different doses. Wegovy (2.4mg weekly) is specifically approved for chronic weight management, while Ozempic (0.5–2mg weekly) is labeled for type 2 diabetes but is widely prescribed off-label for weight loss.
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. Approved for type 2 diabetes in 2022, it entered the obesity treatment market under the brand name Zepbound in 2023. Mounjaro and Zepbound both contain tirzepatide — the same molecule in different FDA-approved contexts.
This matters for a practical reason: the majority of people searching "Ozempic vs Mounjaro" are researching these drugs as weight loss options, even if the version they'll actually use is either Wegovy/Zepbound (brand-name obesity-approved) or compounded semaglutide/tirzepatide (affordable alternatives). All four products work through the same mechanisms as their respective molecules.
How They Work: Single vs Dual Receptor Agonist
This is the key pharmacological difference between the two drugs — and it explains why tirzepatide tends to produce greater weight loss.
Semaglutide is a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone, which is naturally released from the gut after eating. When semaglutide binds to GLP-1 receptors in the brain's hypothalamus (the appetite-regulation center), it powerfully suppresses hunger, reduces food cravings, and increases satiety. It also slows gastric emptying, which means food stays in the stomach longer and extends the feeling of fullness. Additionally, it enhances insulin secretion in response to meals while suppressing glucagon, helping regulate blood sugar.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 receptor (as semaglutide does) AND the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP is another incretin hormone that plays a role in fat storage, insulin secretion, and — when activated pharmacologically — appears to enhance the appetite-suppressing and metabolic effects of GLP-1 agonism. The combined activation creates a synergistic effect that translates into greater weight loss than a pure GLP-1 agonist can achieve alone.
Mechanism at a Glance
| Feature | Semaglutide (Ozempic / Wegovy) | Tirzepatide (Mounjaro / Zepbound) |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Receptors Targeted | GLP-1 only | GLP-1 + GIP |
| Appetite Suppression | Profound | Profound + enhanced via dual agonism |
| Gastric Emptying Slowdown | Yes | Yes |
| Insulin Secretion Enhancement | Yes | Yes (stronger via dual pathway) |
| CV Outcomes Data | SELECT trial: 20% MACE reduction | SURMOUNT-MMO: significant MACE reduction |
Clinical Trial Results: STEP vs SURMOUNT
The most important data for comparing these two medications comes from their landmark phase 3 clinical trials, plus a direct head-to-head comparison study.
The STEP Trials (Semaglutide)
The STEP (Semaglutide Treatment Effect in People with Obesity) trial program enrolled over 4,500 adults with obesity or overweight and at least one weight-related condition. Key results from STEP 1, published in the New England Journal of Medicine in 2021:
- Average weight loss of 14.9% of body weight over 68 weeks at the 2.4mg weekly dose
- 86.4% of participants lost at least 5% of body weight
- 69.1% lost at least 10% of body weight
- 50.5% lost at least 15% of body weight
- Placebo group lost an average of 2.4%, demonstrating the drug's independent contribution
The SELECT cardiovascular outcomes trial (2023) added a critical finding: semaglutide reduced major adverse cardiovascular events (MACE) by 20% in people with pre-existing heart disease — making it the first GLP-1 with proven cardiovascular mortality reduction independent of diabetes status.
The SURMOUNT Trials (Tirzepatide)
The SURMOUNT trial program for tirzepatide delivered some of the most striking weight loss results ever recorded in a randomized clinical trial. SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults:
- At the 5mg dose: average weight loss of 15.0%
- At the 10mg dose: average weight loss of 19.5%
- At the 15mg dose: average weight loss of 22.5% — the highest ever recorded in a phase 3 weight loss drug trial at the time
- 56.7% of participants on 15mg lost at least 20% of body weight (previously a threshold associated with bariatric surgery)
- Results were measured over 72 weeks
Head-to-Head: SURMOUNT-5 Trial
The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in a randomized head-to-head design. At 72 weeks, tirzepatide produced significantly greater weight loss than semaglutide 2.4mg. The difference was approximately 47% greater relative weight loss with tirzepatide. This makes tirzepatide the more effective drug on average — though individual patient response still varies considerably.
Weight Loss Results Comparison
| Drug / Dose | Avg Weight Loss | Lost 5%+ | Lost 15%+ | Lost 20%+ | Trial Duration |
|---|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | ~15% | 86% | 51% | 30% | 68 weeks |
| Tirzepatide 5mg (Mounjaro) | 15% | 89% | 46% | 26% | 72 weeks |
| Tirzepatide 10mg (Mounjaro) | 19.5% | 96% | 67% | 45% | 72 weeks |
| Tirzepatide 15mg (Mounjaro) | 22.5% | 96% | 76% | 57% | 72 weeks |
Side Effects: How Do They Compare?
Both semaglutide and tirzepatide share a similar side effect profile because both activate the GLP-1 receptor. The gastrointestinal system is most commonly affected, particularly during the dose-escalation phase when your body is adjusting to the medication.
Most Common Side Effects (Both Drugs)
- Nausea — most frequent complaint, typically peaks in weeks 2–8 of a new dose, then improves
- Vomiting — less common than nausea but reported in 5–15% of patients
- Diarrhea — occurs in roughly 20–30% of patients at some point during treatment
- Constipation — gastric emptying slows, and some patients shift between diarrhea and constipation
- Injection site reactions — mild redness or bruising at the injection site, typically self-resolving
- Fatigue — particularly in the first weeks of each dose increase
In SURMOUNT-1, nausea occurred in about 31–36% of tirzepatide users at the 10–15mg doses, compared to approximately 44% in the STEP 1 trial for semaglutide. However, these figures come from different trial populations and designs, making direct comparison difficult. Some providers and patients report that tirzepatide's GI side effects feel somewhat different in character — with more nausea early and less at steady state.
Serious but Rare Risks (Both Drugs)
- Thyroid C-cell tumor risk: Observed in rodent studies; has not been confirmed in humans. Both drugs carry an FDA boxed warning. Avoid in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
- Pancreatitis: Rare but reported. Seek immediate care for severe persistent abdominal pain.
- Gallbladder disease: Rapid weight loss (from any cause) increases gallstone risk; GLP-1 drugs are associated with a modestly elevated rate of cholecystitis.
- Hypoglycemia: Rare unless combined with sulfonylureas or insulin in diabetic patients.
Dosing Schedules: What to Expect
Both medications use a gradual dose escalation protocol designed to minimize gastrointestinal side effects while the body adapts. Neither drug produces immediate maximum effects — the titration period typically takes 16–20 weeks to reach the full maintenance dose.
Dose Escalation Schedule
Semaglutide (Ozempic / Wegovy)
Tirzepatide (Mounjaro / Zepbound)
Many patients remain at lower maintenance doses (5–10mg for tirzepatide, 1.0–1.7mg for semaglutide) if they are achieving good results without significant side effects. Dose escalation should always be guided by your provider.
Cost Comparison: Brand-Name vs Compounded
Cost is the defining factor for most patients choosing between these medications — and between brand-name and compounded versions. Here is a complete breakdown of what you can expect to pay in 2026.
Monthly Cost Comparison 2026
| Medication | Brand-Name Cost (No Insurance) | Compounded via Trimi | Savings |
|---|---|---|---|
| Semaglutide (Ozempic / Wegovy) | $900–$1,300/mo | From $99/mo | Up to 92% |
| Tirzepatide (Mounjaro / Zepbound) | $1,000–$1,500/mo | From $125/mo | Up to 91% |
Brand-name costs are list prices without insurance. Actual out-of-pocket costs may vary with insurance coverage, manufacturer savings cards, or patient assistance programs. Compounded pricing reflects Trimi's current program rates and may vary by dose.
Brand-name costs of $1,000–$1,500 per month place these medications out of reach for the majority of Americans without generous prescription drug coverage. Medicare Part D began covering Wegovy for patients with established cardiovascular disease following the SELECT trial, but coverage for weight loss alone remains inconsistent across commercial plans.
This is why compounded alternatives have become the primary access route for most GLP-1 patients in 2026. The FDA permits licensed compounding pharmacies to prepare semaglutide and tirzepatide formulations using pharmaceutical-grade active pharmaceutical ingredients (APIs). Reputable providers like Trimi work exclusively with PCAB-accredited pharmacies and include full medical supervision — matching the clinical experience of brand-name treatment at a fraction of the cost.
Ozempic or Mounjaro: How to Choose
There is no single right answer. The best medication depends on your individual goals, health history, response, and budget. Here is a framework based on the evidence:
Choose Tirzepatide (Mounjaro / Compounded) If:
- You want maximum weight loss potential
- You have type 2 diabetes and want superior glucose control alongside weight loss
- You have already tried semaglutide with suboptimal results
- You can manage the slightly higher upfront cost
- You want the drug with the most impressive clinical trial numbers (22.5% average weight loss at 15mg)
Choose Semaglutide (Ozempic / Compounded) If:
- You have established cardiovascular disease and value the SELECT trial's proven MACE reduction data
- You want the most affordable option ($99/mo through Trimi)
- You are starting your first GLP-1 medication and want to begin with the drug that has the longest safety and efficacy track record
- You have prior experience with semaglutide and good tolerability
- Budget is the primary concern — semaglutide delivers excellent results at a lower price point
For a broader look at how all GLP-1 medications compare, see our best GLP-1 for weight loss 2026 guide. If cost is your main concern, our affordable GLP-1 injections guide covers every option available.
Can't Afford Brand-Name? Compounded Alternatives Through Trimi
The $1,000+ monthly price tag on Ozempic and Mounjaro is the most significant obstacle to access for the 100 million Americans living with obesity. Yet the therapeutic molecules themselves — semaglutide and tirzepatide — can be prepared by FDA-registered compounding pharmacies at a fraction of the retail cost.
Trimi is a telehealth provider that connects patients with licensed medical providers and PCAB-accredited compounding pharmacies. The process is fully online:
- Complete your medical intake — a comprehensive health questionnaire reviewed by a licensed provider in your state
- Receive your prescription — if approved, your provider issues a prescription and selects your starting dose
- Medication ships to your door — compounded semaglutide or tirzepatide is prepared and shipped from a PCAB-accredited pharmacy
- Ongoing support — your provider monitors your progress, adjusts doses, and manages any side effects
Start Your GLP-1 Journey for $99/Month
Trimi offers compounded semaglutide from $99/month and compounded tirzepatide from $125/month — the same molecules as Ozempic and Mounjaro, with full medical supervision included. No insurance required. Free consultation.
Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredients as their brand-name equivalents. The clinical evidence from STEP and SURMOUNT trials — studying the exact same molecules — applies to compounded versions. For a detailed look at the evidence, see our compounded vs brand-name semaglutide comparison.
If you are comparing telehealth providers, our best online weight loss clinics 2026 guide breaks down the top platforms by cost, quality, and patient experience.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss?
Based on head-to-head clinical data, yes — tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy). The SURMOUNT-1 trial showed up to 22.5% body weight reduction with tirzepatide 15mg versus 15% with semaglutide 2.4mg in STEP 1. However, individual responses vary, and some patients do equally well or better on semaglutide.
What is the difference between Ozempic and Mounjaro?
Ozempic contains semaglutide, a single GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. The dual mechanism gives tirzepatide a broader metabolic effect and, on average, greater weight loss. Both are weekly subcutaneous injections. Ozempic is FDA-approved for type 2 diabetes; Wegovy (same molecule) is approved for weight loss. Mounjaro is approved for type 2 diabetes; Zepbound (same molecule) is approved for weight loss.
Can I get compounded Ozempic or Mounjaro?
Yes. FDA-registered compounding pharmacies can legally prepare compounded semaglutide and tirzepatide. These use the same active molecules as the brand-name drugs and work through identical mechanisms. They are significantly more affordable — compounded semaglutide starts at $99/month and compounded tirzepatide at $125/month through providers like Trimi, versus $1,000–$1,500/month for brand-name versions.
Which has worse side effects — Ozempic or Mounjaro?
Both share a similar GI side effect profile: nausea, vomiting, diarrhea, and constipation are the most common. These typically peak during dose escalation and improve over time. Some studies suggest tirzepatide users experience slightly higher rates of nausea early in treatment, though the severity is generally mild. Both drugs carry a boxed warning about thyroid C-cell tumor risk based on animal studies, though this has not been confirmed in human clinical data.
How long does it take to lose weight on Ozempic vs Mounjaro?
Both medications begin reducing appetite within 1–2 weeks of starting. Measurable weight loss typically begins within the first 4 weeks. Meaningful results (5%+ body weight) are usually seen by weeks 8–12. Peak weight loss occurs at the maintenance dose, typically reached after 16–20 weeks of titration. Tirzepatide tends to produce faster weight loss trajectories in clinical trials, but both require sustained treatment for optimal results.
Which is cheaper — Ozempic or Mounjaro?
Brand-name prices are similar: Ozempic and Wegovy run approximately $900–$1,300/month without insurance; Mounjaro and Zepbound run $1,000–$1,500/month. With compounding, tirzepatide is slightly more expensive than semaglutide due to synthesis complexity. Through Trimi, compounded semaglutide starts at $99/month and compounded tirzepatide at $125/month — a savings of 85–90% versus brand-name.
Do I need a prescription for Ozempic or Mounjaro?
Yes. Both semaglutide and tirzepatide require a valid prescription from a licensed healthcare provider. Telehealth platforms like Trimi simplify this process — you complete a medical intake online, a licensed provider reviews your health history, and if appropriate, issues a prescription that goes directly to a licensed compounding pharmacy. The entire process typically takes 24–48 hours.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Ozempic (semaglutide) and Mounjaro (tirzepatide) are prescription medications that require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved but are prepared by licensed pharmacies under applicable federal and state regulations. Individual results vary. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.
More on GLP-1 Drug Comparisons
Best GLP-1 for Weight Loss 2026
Full rankings of every GLP-1 medication by efficacy and value
Compounded Semaglutide vs Brand-Name Wegovy
Is compounded semaglutide as effective as Wegovy?
Best Online Weight Loss Clinics 2026
Top telehealth providers for GLP-1 access compared
Affordable GLP-1 Injections 2025
How to access GLP-1 therapy without breaking the bank
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Wadden TA et al. SURMOUNT-5: Tirzepatide vs. Semaglutide Head-to-Head Comparison for Weight Management. N Engl J Med. 2025.
- FDA Prescribing Information for Wegovy (semaglutide injection) 2.4mg. Novo Nordisk, 2023.
- FDA Prescribing Information for Zepbound (tirzepatide injection). Eli Lilly, 2023.